RBC Capital lowered the firm’s price target on Vertex Pharmaceuticals to $347 from $350 and keeps a Sector Perform rating on the shares. The company reported a “steady” quarter that highlighted its durable long-term cash flow potential, though its maturing CF franchise underscores the importance of generating outstanding clinical and commercial outcomes in its pipeline to drive significant stock upside from here, the analyst tells investors in a research note. RBC adds that its reduced price target reflects slightly lowered CF estimates, offset by increased exa-cel probability of success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $408 from $399 at Barclays
- Vertex raises FY23 CF product revenue view to about $9.85B
- Vertex Pharmaceuticals reports Q3 EPS $3.98, consensus $3.97
- Fly Insider: Barnes Group, Palo Alto among week’s notable insider trades
- Notable companies reporting after market close